Ema, Crofelemer obtains an additional orphan drug designation also for microvillary inclusion disease (MVID)

After being designated for Short Bowel syndrome (SBS) last December 2021, Napo Therapeutics gains another…

Application for ODD for Crofelemer, a rare gastrointestinal pathology

Napo Therapeutics, a pharmaceutical company whose goal is to develop therapies that make a difference…

Relations with the media

SEC Newgate – Via Ferrante Aporti 8, Milano

Federico Ferrari

+39 347 645 6873

Diana Zogno

+39 333 904 8721